StreetInsider.com News Articles

Autonomix Medical Selected for Best Innovation Competition at CRT 2026

Thu, 05 Mar 2026 08:45:00 -0500

THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its presentation titled, “Illuminating The Nervous System With Transvascular Precision-guided Technology,” has been selected for oral presentation in the Best Innovation Competition at Cardiovascular Research Technologies (CRT) 2026.

The presentation will be delivered by Chief Executive Officer, Brad Hauser, on Monday, March 9, 2026, from 4:19 PM to 4:27 PM ET in the International Ballroom –

Autonomix Medical Selected for Best Innovation Competition at CRT 2026

Thu, 05 Mar 2026 08:45:00 -0500

The presentation will be delivered by Chief Executive Officer, Brad Hauser, on Monday, March 9, 2026, from 4:19 PM to 4:27 PM ET in the International Ballroom –

Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis

Wed, 04 Mar 2026 08:40:00 -0500

THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC.

The abstract titled, “Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes,” will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 -

Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis

Wed, 04 Mar 2026 08:40:00 -0500

Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation

Wed, 25 Feb 2026 08:30:00 -0500

CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement

THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser.

As part of the segment, Mr. Hauser discusses Autonomix’s publication strategy and the Company’s focused efforts over the past 12 to 18 months to expand its scientific publication and

Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation

Wed, 25 Feb 2026 08:30:00 -0500

CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement

As part of the segment, Mr. Hauser discusses Autonomix’s publication strategy and the Company’s focused efforts over the past 12 to 18 months to expand its scientific publication and

Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation

Thu, 19 Feb 2026 08:30:00 -0500

THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Clarke Wilkirson, PhD, Clinical Development Engineer II, will present new long-term clinical data at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, happening March 5-7, 2026, in Phoenix, Arizona.

The presentation, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation” (Submission ID: 2249416), has been accepted as an oral podium presentation. Dr. Wilkirson will

Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation

Thu, 19 Feb 2026 08:30:00 -0500

Form 10-Q Autonomix Medical, Inc. For: Dec 31

Wed, 11 Feb 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260211/25984494.html

Form 10-Q Autonomix Medical, Inc. For: Dec 31

Wed, 11 Feb 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260211/25984494.html

Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting

Wed, 28 Jan 2026 08:30:00 -0500

THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that final clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting happening February 4-8, 2026 in Savannah, GA.

The presentation, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Final Analysis of Neurolysis via Transvascular Radiofrequency (RF) Ablation,” has been accepted as an ePoster presentation

Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting

Wed, 28 Jan 2026 08:30:00 -0500

Form 8-K Autonomix Medical, Inc. For: Jan 14

Fri, 16 Jan 2026 07:30:00 -0500

si-local-file:///var/storage/secattach/20260116/25857860.html

Form 8-K Autonomix Medical, Inc. For: Jan 14

Fri, 16 Jan 2026 07:30:00 -0500

si-local-file:///var/storage/secattach/20260116/25857860.html

Form 8-K Autonomix Medical, Inc. For: Jan 09

Fri, 09 Jan 2026 09:11:00 -0500

si-local-file:///var/storage/secattach/20260109/25829716.html

Form 8-K Autonomix Medical, Inc. For: Jan 09

Fri, 09 Jan 2026 09:11:00 -0500

si-local-file:///var/storage/secattach/20260109/25829716.html

Autonomix Medical presents pancreatic cancer pain study at ASCO conference

Fri, 09 Jan 2026 08:45:54 -0500

Autonomix Medical Inc. (NASDAQ: AMIX) presented clinical data from its proof-of-concept study at the 2026 ASCO Gastrointestinal Cancers Symposium showing pain reduction in pancreatic cancer patients across disease stages.

The subgroup analysis examined outcomes from the company's ongoing Proof-of-Concept 1 study, which evaluates a transvascular radiofrequency denervation platform for treating severe pancreatic cancer-related pain. The analysis included patients with Stage 2 through Stage 4 pancreatic cancer.

According to the data presented, responding patients showed pain reduction within 24 hours of the procedure. At seven days post-procedure, 93.75% of responding patients improved from severe pain to mild or moderate pain levels. At four

Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium

Fri, 09 Jan 2026 08:45:00 -0500

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options

THE WOODLANDS, TX, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages. The analysis expands upon previously reported

Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium

Fri, 09 Jan 2026 08:45:00 -0500

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options

Autonomix Medical receives European patent for cardiac nerve therapy

Tue, 30 Dec 2025 08:31:12 -0500

Autonomix Medical Inc. (NASDAQ: AMIX) received European Patent No. EP4230133 from the European Patent Office for systems and methods that sense autonomic and cardiac signals to deliver precision nerve-targeted treatments for cardiac tissues.

The patent covers technology that maps targets and delivers therapy with closed-loop feedback to perform neuromodulation, denervation, and ablation of cardiac tissues. The system addresses applications including arrhythmias, heart failure, hypertension, and refractory angina pain.

"This European patent represents another important milestone in strengthening and expanding the global IP foundation behind our breakthrough technology platform," said Brad Hauser, CEO of Autonomix Medical.

The patent relates to systems for performing treatment,

Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology

Tue, 30 Dec 2025 08:30:00 -0500

With over 80 issued patents and 39 pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation

Newly granted patent further strengthens the Company’s strategic position in a multi-billion-dollar market opportunity, unlocking potential across cardiovascular, renal, and other high-burden diseases

THE WOODLANDS, TX, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the European Patent Office (EPO) has granted Patent No. EP4230133 (the ‘133 patent), titled, “Controlled and

Autonomix Medical, Inc. Granted European Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology

Tue, 30 Dec 2025 08:30:00 -0500

With over 80 issued patents and 39 pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation

Newly granted patent further strengthens the Company’s strategic position in a multi-billion-dollar market opportunity, unlocking potential across cardiovascular, renal, and other high-burden diseases

THE WOODLANDS, TX, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the European Patent Office (EPO) has granted Patent No. EP4230133 (the ‘133 patent), titled, “Controlled and

Autonomix Medical discusses IP strategy and platform expansion plans

Tue, 23 Dec 2025 08:45:53 -0500

Autonomix Medical Inc. (NASDAQ: AMIX) participated in a Virtual Investor CEO Connect segment, where CEO Brad Hauser outlined the company's strategic priorities.
Hauser highlighted two key areas of focus for the medical device company: strengthening intellectual property protection for its platform and evaluating opportunities beyond pancreatic cancer treatment. The potential new applications include cardiovascular, pulmonary and interventional pain management areas.
Autonomix develops catheter-based microchip sensing array technology designed to detect and differentiate neural signals. The company states its technology may offer greater sensitivity than currently available technologies for transvascular diagnosis and treatment of diseases involving the peripheral nervous system.
The company is initially

Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment

Tue, 23 Dec 2025 08:45:00 -0500

Access the segment here

THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it recently participated in a Virtual Investor CEO Connect segment.

As part of the segment, Brad Hauser, CEO of Autonomix, outlined two key priorities shaping the Company’s trajectory: strengthening its platform through intellectual property protection and evaluating opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary

Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment

Tue, 23 Dec 2025 08:45:00 -0500

Access the segment here

THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it recently participated in a Virtual Investor CEO Connect segment.

As part of the segment, Brad Hauser, CEO of Autonomix, outlined two key priorities shaping the Company’s trajectory: strengthening its platform through intellectual property protection and evaluating opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary